Skip to content

Decision-making - the Benefit of Bedside CRP Within Ambulance Care

When Triage is Insufficient - the Benefit of Bedside CRP Within Ambulance Care

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04097210
Acronym
Q-CRP
Enrollment
110
Registered
2019-09-20
Start date
2016-01-01
Completion date
2021-06-01
Last updated
2022-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Keywords

Q-CRP, lactate, suPAR, POC, ambulance

Brief summary

Patients with degreased (DGC) for ambiguous reasons receive low triage priority. Their death risk is triple. Tools are needed to identify the critically ill patients from this group. The triage used today is not effective. The bedside point-of-care measurements are CRP, lactate acid and suPAR (Soluble Urokinase Plasminogen Activator Receptor). Elevated values associate with the probability of critical illness and predict a risk of death.

Detailed description

Purpose: To improve identification and proper prioritization of patients with non-specific symptoms prehospitally, we intend to investigate whether Q-CRP, a rapid test for CRP, correlates with time-critical states in the above-mentioned patient group alone or together with CRP, lactate and suPAR. The primary endpoint is need for hospital care. Material: Patients over 18 years who exhibit non-specific symptoms and transported to the emergency room. Method: In patients with unspecified conditions, defined according to the inclusion template, a venous blood sample was taken prehospitally at the scene by the EMS. Analysis: Significance tests and regression analyzes with 95% CI were used. The diagnostic accuracy of Q-CRP, lactate, suPAR and combinations thereof were compared with optimal boundary values.

Interventions

DIAGNOSTIC_TESTPOC

Sponsors

Helsinki University Central Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 104 Years

Inclusion criteria

* Patients over 18 years who exhibit non-specific symptoms and transported to the emergency room.

Exclusion criteria

* Abnormal vitals

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with high suPAR level24 hoursA high suPAR level, e.g. above 6 ng/ml

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026